I saw that ask today and scratched my head. WTF are they passing around in the break room. Granted the ticker needs cash been stuck on 5k cash at hand since jan but without any news that RBSH is moving forward in a positive way I don't think there is a long list that will jump on the 1.7 mil ask.

FYI: on a sad note Craig Dionne PHD founding partner of GENSPERA (later Inspyr and now Rebus) passed away at age 65. A real smart guy who took the vision of a plant based compound and took it thru trials to form the FDA approved drug Mipsagargin. Unfortunately he has passed before Mipsagargin became the block buster drug he envisioned.

There is really not much to update other than what little we all get in the filings. Mipsagargin the first and original drug that spawned interest in GNSZ/NSPX and now RBSH has been on the shelve for a few yrs. Although fairly well received in Ph II trials it never has got the necessary financing to progress into PH III. Currently RBSH has hitched its success to adenosine receptor antagonist RT-AR001. The drug has completed in VITRO studies and RBSH has contracted suppliers to manufacture enough of the drug to carry thru the next step in VIVO studies and once approved start clinical trials. As usual for clinical stage bios money is the problem. RBSH is currently out of cash and needs financing to carry out the plans set forth in the filings. The CEO Raul Silvestre is currently financing the necessary expenses to provide the SEC with the necessary filings and is accruing those expenses. Silvestre Law group is owed over $300K and also holds a $290K convertible loan (debenture). Hopefully, the next few months will provide some financing news and RT-AR001 can move forward on the way to FDA approval.

He has as of end of 3rd quarter $600K reasons to make something happen, probably more by now. The company has a balance due to Silvestre Law Group of $309,848 at September 30, 2022. Silvestre Law Group also holds $290,000 of our convertible debentures at September 30, 2022.

Couple notes concerning past associates. Chris Lowe former CEO left Inspyr and took a CFO position at Cortexyme. When it's Alzheimer drug failed the stock dropped and company was taken over by Quince Therapeutics. Chris Lowe and most of Cortexye employees were let go. He has since found a CEO position at a private Company Nusano. He has moved around so maybe he can find a home with his new position. Colin Hislop president of Ridgeway Therapeutics (developer of RT-AR001) has worked for Eiger BioPharma since 2019 but has subsequently be moved out of his SVP position as a new CEO has taken over. The stock of Eiger has underperformed. He is currently looking for another position. Lots of comings and goings at Genspera, Inspiry and Rebus but the constant is Raul Silvestre.

Got 134k in till. First 9 months average 64k per month. Owe 6mil +\- . I would think that something needs to happen in 23. Sort of puzzling why Sabby hasn’t shown up with their usual convertible loan!

3rd quarter 10-Q filing late but at least they are filing! The till must be getting cleaned out by now and with no news of funding something may have to develop to keep lights on going forward. Very possible that RT-AR001 stagnates similar to Mipsagargin while some funding or activity to the drug platform evolves!

Ticker has been dead.. highest volume today since June..one trade of 400,000 shares. Filing is due soon so just maybe something?

From recent 8-K... "substantial doubt as to the Company's ability to continue as a going concern" language has been in every 10-K filed. Why it's a problem now is anyone's guess. However, there is probably more to the story than divulged especially since year end audit is only a couple months away.

Oct 8 2020 NSPX takes back patent from Ridgway to develop RT-AR001.
Oct 12 2021 NSPX completes merger and acquisition by RBSH
What is the Oct surprise for 2022? You would think that eventually Silvestre would show his hand!!

Tic Toc ... time is running. On current spending trend the cash in the till may hit 0 sometime in October. If Silvestre has any irons in the fire he may float another convertible along with the 290K he has already. Obviously, RBSH needs cash to carry on but from whom and at what cost.

As per last filing 265K left in the cash account. Went thru almost 500K in first 6 months of 22. Doesn't seem RBSH will make it thru the remaining 6 months of 22 without influx of cash. Interesting to see if Silvestre will get Sabby to pony up another 500K debenture or maybe Silvestre has somethin else up his sleeve! Inquiring minds would like to know!

Silvestre Law group gets 10k per month to handle SEC compliance paperwork.. it is also owed 309 k for misc billed legal work .. it is also holding a 290K convertible debenture. Raul Silvestre has many reasons to get something going with this ticker.

Came off its recent lows and moved to .025 then retraced on low/no volume to +/- .02. IF it soon breaks thru .025 and IF there is ANY positive news or news on RT-AR001 in upcoming 10-Q (august 15) a move higher may be forthcoming. Anyway its worth the wait and see what's up with this ticker!! Most have given this play up for dead.

doing better lately.. no sellers stepping up. Maybe forming a base here for a parabolic move if 1. gets the 5 million investment prior to oct.. 2. positive news concerning IND for RT-AR001.. 3. If our CEO is working the phones for some kind of deal!

Broke out of the months long channel .. time will tell if this is a start of further upside.

Cleared in VITO study now in VIVO prior to IND application. If/when it clears in VIVO and moves to approved IND application .10 may be low end of future PPS.

Stuck in the middle of a channel between .015 and .008 for most of 2022. Low volume, no news, no website, no upgrade.. come on man Silvestre where are you?

Agreed: From 8-K 10/12/21....The company expects to provide a further clinical update in the first half of 2022. The Company is also in the process of launching and rebranding its new corporate website at www.rebus-corp.com.
The company anticipates that subsequent to the reverse split it will be able to apply to list its Common Stock on the OTCQB tier of the OTC Markets Group, and eventually apply for a listing on a national exchange, in order to provide stockholders with more liquidity and allow the company more flexibility in accessing the capital markets.

I guess Silvestre is behind schedule on some of his ambitions noted in the merger documents. However, like most things these days he can blame covid as the root cause of the delays.

From 10-K ...Possible clinical trials to begin later in 2022 or early 2023???

Between September 2021 and February 2022, our CMO manufactured to GMP standards; both our adenosine A2A receptor antagonist as well as the nano- or microparticle formulation for intratumoral delivery known as RT-AR001. We have sufficient material to take us through the IND and initial clinical studies.
We have completed in-vitro testing of our adenosine A2A receptor antagonist and will begin in-vivo animal testing with RT-AR001 in Q2 2022. The Company plans to provide a further update on RT-AR001’s clinical development in the second half of 2022.

Noticed that NSPX ex-CEO Chris Lowe is back in CEO chair after a management shake up of Cortexyme after a failed trial of their Alzheimer drug sent stock price from $120.00 to $5.00..Good luck Chris!

even if o/s is dbl what was posted in 10/31 the cap would be low if the FDA gives RT-AR001 the approval to start clinical trials. All are hanging their hat on the fact the IND approval for the drug is forthcoming from FDA.

Price has been holding around .01 for awhile.. not to say it can't slip to low dbls.. but it has known to spike hard with any tidbit of info..10-K due end of march so maybe something? You would think Silvestre being a smart man and Pepperdine grad would at least try to make something of this ticker!

Back to being a true penny (one) stock for the day LOL

Yes retail has left the building.. The fan base is left with Sabby, some starry eyed speculators and bag holders. The actions of this ticker has driven most away...the ticker has been the poster child of dead money with no news, unmet promises, borrowing, dilution and RS. Silvestre has taken over the CEO probably because they didn't waste their time looking for someone to take the dead end job. The only hope is that Silvestre can put something together to get out from under this stock and move on. One thing you can expect is that the company will be out of money soon so another $500,000 loan from Sabby will be forthcoming.

You may be correct on that .002. No one should trust his ticker. Waterboarding would be more humane than the abuse this company had dealt out to investors over the years. Years without communication from management...missed filings... zero substantial press releases... deals with toxic lender...dilution dilution dilution ... and to keep the good times rolling RS after RS. There was talk that mipsagargin was the best thing since canned beer ... now not a word! We are on to RT-AR001 if it ever gets off the ground. Only time will tell what will happen to the tickers vast IP (intellectual Property) which at the current time is worth very little.

That would be a record low for the ticker.. I remember it getting to .003 some time in the past but that is the lowest I can recall. It did rally some what from those lows but all rallies in the past were hindered by dilution and eventual RS. A very sad reoccurring event for investors that have believed that substantial value for this company is just around the proverbial corner.

Yes.. if there is no end for the dumping of shares on the market Dbls is in the future. Silvestre has been general consul for years and has been behind all the transactions of this company and never once has defended the stock price. I may be wrong but there will be no new permanent CEO.. no new web site.. no up list to any exchange, no new list of investors.. but what there will be is more borrowing money to stay alive and file reports.. more issuing share to pay off debt.. all for the purpose to unload all or portions of the company for what he can get. An approved IND for RT-AR001 may be the catalyst.

The business model of borrowing money thru convertible debentures to keep filings current and keep the lights on then issuing mega blocks of stock (diluting) to pay off convertibles has been the trend in place for a while. Silvestre has been the architect of this plan. Nothing has happened to think this plan will not continue. As the PPS erodes more stock is needed to pay of the loans. If some event does not happen to change this trend expect business as usual with this ticker.

Many have been very successful by using technical analysis to predict price movements. Not so much with past technicians regarding this stock. The constant issuing of stock (dilution) will drive the stock price down. Until some value is confirmed (or hints of value) for the drug platforms expect business as usual. Once value is determined herd mentally will take over and spike the PPS. There is a lot of stored up energy to drive this ticker higher if good news ever materializes!

Eventually the masterminds of Rebus Holding (RBSH) may show their hands and let us all know what is up going forward.

yes that has been business as usual with this ticker but what's with the Holding Co. NSPX has been RS and diluting several times since 2016 on their own. I know Silvestre is a lawyer but even a few lawyers may have their reputation to uphold. This Holding Company must have some motive other than how fast it can bilk investors.

Could easily RS NSPX and diluted like the last few times... a Holding Company for what reason??? Why other than some like pennies for covering the lower bids every day!!

You would have to think that this latest move (Rebus Holdings) by Silvestre has developments that of yet have not been realized. A "method to their madness" as they say. No website...no application for up list.. no news on drug related issues. With a new year maybe some of these issues will be addressed. Mipsagargin continues to be modified (latest 12/18/21) in Drug Chem so some entity is studying and fine tuning the drug for some reason. Wait and see what happens is still strategy going into 2022.

Silvestre and/or Silvestre Law Group is owed approximately $500,000 (250,000 account receivable and 250,000 debenture) from inspyr. Odd he would let this pps free fall since the RS. It's obvious pps does not matter to him!

Thx.. that report is so right on. Once they ran off Dr. Dionne there was no one to champion the potential of Mipsagargin. Chris Lowe could hardly spell mipsagargin let alone promote the drug's capabilities. His only action was to shut everything down, shelve the drug and delay the research. Maybe reports like these will renew interest in the drug that may be a valid cancer killer.

Have no idea what it means or if it means anything...but mipsagargin continues to be modified in PUBCHEM (11/27, 12/05, 12/11)???

Financing will be needed in 2022 ... will Rebus go to Sabby for more loans (convertible debentures) to finance operations or will Silvestre find some actual investors or partners that are willing to put their money on the line.

For sure you got this right.. many have come and gone from this ticker and many (including myself) are holding a bunch of discounted shares of this company waiting for that elusive catalyst that may or may not come.

You may be correct in your thinking it has happened before...however the new Rebus has yet to move anything forward (no web site, no application for up list, no news on drug platforms)...these items were mentioned in filings and may be forthcoming so it may be possible that the pps will be >.10 before it is <.01.